Neurozen Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 6

Neurozen General Information

Description

Developer of a diagnosis technology designed for the early detection of Alzheimer's. The company uses advanced, deep learning-enabled neuroimaging and genetic services for risk assessment and early detection, enabling doctors to treat the disease before irreversible brain damage or cognitive decline has occurred.

Contact Information

Website
www.neurozen.ai
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 5th Floor, 413, Teheran-ro
  • Seoul, Gangnam-gu
  • South Korea
+82
Primary Industry
Diagnostic Equipment
Other Industries
Other Healthcare Technology Systems
Corporate Office
  • 5th Floor, 413, Teheran-ro
  • Seoul, Gangnam-gu
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neurozen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Accelerator/Incubator 01-Jan-2023 Completed Generating Revenue
1. Later Stage VC (Series A) 29-Jul-2021 Completed Generating Revenue
To view Neurozen’s complete valuation and funding history, request access »

Neurozen Patents

Neurozen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023068619-A1 Method for predicting cognitive impairment by using spatiotemporal memory test and brain image information, device for performing same, and computer-readable recording medium Inactive 22-Oct-2021
WO-2023068732-A1 Method for acquiring score for neuropsychological test, neuropsychological test apparatus performing same, and computer-readable recording medium Inactive 18-Oct-2021
WO-2023013959-A1 Apparatus and method for predicting amyloid beta accumulation Inactive 03-Aug-2021
WO-2022114526-A1 Single nucleotide polymorphism marker for predicting risk of alzheimer's disease and use thereof Inactive 25-Nov-2020 C12Q1/6883

Neurozen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neurozen Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Colopl Next Corporate Venture Capital Minority
DT & Investment Corporate Venture Capital Minority
Friend Investment Partners Venture Capital Minority
Friend Investment Partners (Seoul) Venture Capital Minority
i Plus Center Corporation Minority
You’re viewing 5 of 6 investors. Get the full list »

Neurozen FAQs

  • When was Neurozen founded?

    Neurozen was founded in 2015.

  • Where is Neurozen headquartered?

    Neurozen is headquartered in Seoul, South Korea.

  • What is the size of Neurozen?

    Neurozen has 6 total employees.

  • What industry is Neurozen in?

    Neurozen’s primary industry is Diagnostic Equipment.

  • Is Neurozen a private or public company?

    Neurozen is a Private company.

  • What is Neurozen’s current revenue?

    The current revenue for Neurozen is .

  • Who are Neurozen’s investors?

    Colopl Next, DT & Investment, Friend Investment Partners, Friend Investment Partners (Seoul), and i Plus Center are 5 of 6 investors who have invested in Neurozen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process